YuhanCDMO has operated as a pharmaceutical API manufacturer for over four decades. What began as a single facility producing anti-tuberculosis compounds has grown into a two-site CDMO network with regulatory clearances spanning the U.S., Europe, Japan, and Latin America, and a service range that covers the full development-to-commercial manufacturing continuum. Going forward, our priorities reflect where the industry is heading.
We are increasing our clinical-stage API manufacturing capacity to engage partners at the IND-filing stage. We are maintaining and expanding our multi-regulator inspection record across key global markets. And we are continuing to invest in the quality, environmental, and safety management systems that global pharmaceutical partners require of their suppliers.